Sanofi to Cut 900 Jobs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sanofi to Cut 900 Jobs



Sanofi is planning to shed approximately 900 jobs in France in the lead up to 2015 as it seeks to implement certain key strategic objectives.

In a press statement, Sanofi explained that reduction measures could involve early retirements, mobility proposals and repositioning within France. No relocation of sites or any changes to the number of industrial sites is planned in France; however, the company also added that the function of its Toulouse site “remains to be specified”. Over the summer, the company identified potential stakeholders who could maintain the site’s scientific or technological capacity and a working group will be established shortly to explore all available options. The company hopes to have a firm solution for the site within the coming months.

The workforce reduction is being undertaken to achieve three strategic objectives that the company first revealed at the beginning of July 2012. Sanofi is seeking to improve the momentum and success of research activities; improve the economic performance of Sanofi Pasteur’s industrial units; and streamline support functions.

In the led up to 2015, Sanofi intends for its R&D activities in France to evolve to strengthen the company’s scientific, academic and private network. Plans include progressively adapting the Montpellier site into a strategic centre focused on development, and increasing research activities in Vitry/Alfortville and Chilly-Mazarin/Longjumeau. In addition, Sanofi intends to create a global center of excellence in infectious diseases in Lyon.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here